Actively Recruiting
Antiplatelet Therapy and Endothelial-stabilizing Agents in Cerebral Small Vessel Diseases
Led by The First Affiliated Hospital with Nanjing Medical University · Updated on 2025-03-28
300
Participants Needed
1
Research Sites
56 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Cerebral small vessel disease (cSVD) is a common accompaniment of aging. Recent small subcortical (or lacunar) infarcts (i.e. symptomatic cSVD) and white matter hyperintensities are typical cSVD lesions on neuroimaging. cSVD causes about a quarter of ischaemic strokes and related with cognitive dysfunction. However, few studies are available so far to especially explore the treatment of cSVD. Endothelial dysfunction plays an important part in cSVD. Cilostazol and isosorbide mononitrate have endothelial protective function. We designed this prospective cohort study in China, aiming to evaluate the effect of different antiplatelet agents (e.g. Cilostazol) on cSVD and retina in patients with cSVD (recent small subcortical infarcts or WMH, respectively).
CONDITIONS
Official Title
Antiplatelet Therapy and Endothelial-stabilizing Agents in Cerebral Small Vessel Diseases
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 30 and 79 years
- Recent small subcortical infarct within 3 weeks before enrollment or white matter hyperintensities graded 2-3 on Fazekas scale
- No signs or symptoms of cortical dysfunction such as aphasia, apraxia, agnosia, agraphia, or visual field defects
- Modified Rankin score of 4 or less
- No other pathology in parent artery at the penetrating artery origin
- No significant carotid or vertebral artery stenosis (less than 30%) if lesion is in corresponding territory
- No major-risk cardioembolic sources that require anticoagulation
- Willing and able to participate in follow-up visits and reachable by phone
- Understands study purpose and requirements and has signed informed consent
You will not qualify if you...
- Intracranial aneurysms needing surgery or other major neurological illnesses like seizures, multiple sclerosis, brain tumor (except meningioma), or vascular malformations
- Active heart disease including atrial fibrillation, recent heart attack, angina, or heart failure
- History of any brain bleeding (parenchymal, subarachnoid, subdural, epidural)
- Allergy or contraindication to aspirin, clopidogrel, cilostazol, isosorbide mononitrate, or statins
- Active peptic ulcer, recent major bleeding, bleeding disorders, low platelets or hematocrit, clotting abnormalities, substance abuse, uncontrolled severe high blood pressure, severe liver or kidney impairment, or very high creatine kinase levels
- Major surgery within 30 days before enrollment or planned within one year after
- Dementia or psychiatric conditions preventing reliable evaluation or follow-up
- Other medical conditions limiting survival to less than one year
- Pregnancy, breastfeeding, planning pregnancy, or unwilling to use contraception
- Unable to tolerate MRI
- Participation in another conflicting clinical study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
the First affiliated hospital of Nanjing Medical University
Nanjing, Jiangsu, China, 210001
Actively Recruiting
Research Team
Z
Zhaolu Wang, MD
CONTACT
X
Xinyu Chen
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here